Free Trial
OTCMKTS:IGXT

IntelGenx Technologies Q1 2024 Earnings Report

IntelGenx Technologies logo
$0.17 0.00 (0.00%)
As of 04/25/2025

IntelGenx Technologies EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

IntelGenx Technologies Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IntelGenx Technologies Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

IntelGenx Technologies' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Earnings Documents

IntelGenx Technologies Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More IntelGenx Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IntelGenx Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IntelGenx Technologies and other key companies, straight to your email.

About IntelGenx Technologies

IntelGenx Technologies (OTCMKTS:IGXT), a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

View IntelGenx Technologies Profile

More Earnings Resources from MarketBeat